Nintedanib is a prescription medication classified under respiratory health. It is available as a 100 mg capsule (cap) and is approved for the treatment of certain fibrotic lung conditions. In Hong Kong, the Drug Office of the Department of Health evaluates and authorizes its use based on safety and efficacy data submitted by the manufacturer. Nintedanib is marketed internationally under brand names such as Ofev, but the active ingredient itself is widely prescribed in its generic form.
Nintedanib is a tyrosine kinase inhibitor that blocks several growth factor receptors involved in tissue scarring, including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) receptors. By inhibiting these pathways, the drug reduces the activation, proliferation, and migration of fibroblasts-the cells responsible for producing excess collagen and extracellular matrix in the lungs. This action helps slow the progression of pulmonary fibrosis, leading to a slower decline in lung function. The medication is taken orally, with peak plasma concentrations reached within a few hours after ingestion. Its metabolism is primarily hepatic, involving the enzyme CYP3A4, and it is excreted mainly via feces.
These approvals are based on randomized controlled trials that demonstrated a reduction in the rate of decline of forced vital capacity (FVC), a key measure of lung function.
Researchers are evaluating nintedanib in other fibrotic disorders such as:
Disclaimer: Off-label use of nintedanib requires medical supervision and individualized risk assessment. Patients should discuss potential benefits and risks with a qualified healthcare provider before initiating therapy for unapproved conditions.
Patients should inform their healthcare provider of all prescription medicines, over-the-counter drugs, supplements, and herbal products before starting nintedanib.
Note: Dosing must be individualized. Typical regimens for tyrosine-kinase inhibitors in this class start at 100 mg once or twice daily and are adjusted based on tolerability and liver function tests.
Regular follow-up with a pulmonologist or respiratory specialist is essential for optimal disease management.
This article provides educational information about nintedanib and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Persistent diarrhea should be reported to your healthcare provider promptly. Management may include dietary adjustments, hydration, and possibly anti-diarrheal medication. In some cases, dose reduction or temporary interruption of therapy may be recommended.
Yes, nintedanib can be co-prescribed with pulmonary hypertension drugs, but potential interactions-especially with agents metabolized by CYP3A4-should be reviewed by a clinician to avoid altered drug levels.
Nintedanib capsules are permitted for personal medical use when carried in original packaging with a prescription label. Keep them in your carry-on luggage to avoid temperature extremes and ensure you have a copy of the prescription for customs authorities.
The generic 100 mg nintedanib capsule is typically white to off-white and may bear the imprint “NIN 100” or a similar manufacturer-specific code. Verify the imprint with the dispensing pharmacy if you have any doubts.
Nintedanib inhibits multiple tyrosine kinases, while pirfenidone’s mechanism involves modulation of cytokines and growth factors. Both slow lung function decline, but they have distinct side-effect profiles and dosing schedules, making individual patient factors important in drug selection.
Mild elevations should be evaluated by a healthcare professional. If liver enzymes are within safe limits, treatment may commence with close monitoring; significant elevations usually contraindicate initiation.
No specific food is prohibited, but taking the capsule with food reduces gastrointestinal irritation. Avoid excessive alcohol to minimize additional liver stress.
Store the capsules in a cool, dry place away from direct sunlight. If ambient temperatures exceed the recommended range, keep the medication in a temperature-controlled cabinet or insulated container.
Informing a health professional conducting the screening is advisable, as certain laboratory tests (e.g., liver function) may be required. Disclosure to an employer is not mandatory unless workplace policies specifically address medication use.
Elderly individuals may experience increased sensitivity to side effects, particularly gastrointestinal upset and liver enzyme changes. A lower starting dose or slower titration may be considered based on clinical judgment.
